A 32-year-old woman presents with a 3-week history of persistent dry cough, low-grade fever, and dyspnea. Chest X-ray shows bilateral interstitial infiltrates. Sputum culture and routine bacterial cultures are negative. Serological testing is positive for Mycoplasma pneumoniae IgM. What is the drug of choice for this patient?

Explanation

## Mycoplasma pneumoniae Infection & Macrolide Therapy ### Clinical Context Mycoplasma pneumoniae causes "atypical pneumonia" characterized by: - Insidious onset with dry cough and constitutional symptoms - Bilateral interstitial infiltrates on imaging - Negative routine bacterial cultures (lacks cell wall) - Positive serology (IgM antibodies) ### Why Azithromycin is First-Line **Key Point:** Macrolides (especially azithromycin) are the gold standard for Mycoplasma pneumoniae because: 1. Excellent intracellular penetration — Mycoplasma resides intracellularly 2. Binds 50S ribosomal subunit, inhibiting protein synthesis 3. Superior lung tissue concentration 4. Oral bioavailability allows outpatient management 5. Broad coverage of atypical organisms (Mycoplasma, Chlamydia, Legionella) **High-Yield:** Azithromycin is preferred over erythromycin due to: - Better tolerability (fewer GI side effects) - Longer half-life (5 days) → shorter course (3–5 days) - Superior tissue penetration - Lower drug interaction potential ### Mechanism of Action **Mnemonic:** MACROLIDES = **M**acrolides **A**ct on **C**ells **R**equiring **O**xygen (intracellular pathogens) — **L**ike **I**ntracellular **D**wellers **E**xpelled by **S**ynthesis inhibition Macrolides inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide elongation. This is bacteriostatic, making them ideal for infections where immune clearance is intact. ### Dosing in Mycoplasma Pneumoniae - **Azithromycin:** 500 mg on day 1, then 250 mg daily for 4 days (or 500 mg daily × 3 days) - **Alternative (if macrolide allergy):** Fluoroquinolone (levofloxacin, moxifloxacin) or doxycycline **Clinical Pearl:** Symptoms may persist for 1–2 weeks despite appropriate therapy; this does not indicate treatment failure. Mycoplasma-induced immune phenomena (cold agglutinins, hemolytic anemia) may require additional management. ### Why Other Options Fail | Drug | Reason for Inadequacy | |------|----------------------| | **Ceftriaxone** | No cell wall in Mycoplasma; β-lactams ineffective | | **Fluoroquinolone** | Second-line; reserved for macrolide allergy or resistance | | **Amoxicillin-clavulanate** | β-lactam; ineffective against Mycoplasma | [cite:KD Tripathi 8e Ch 48]